Achieve Life Sciences, Inc (ACHV)

Etorro trading 970x250
Achieve Life Sciences, Inc (ACHV) Logo

About Achieve Life Sciences, Inc

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada. Address: 1040 West Georgia Street, Vancouver, BC, Canada, V6E 4H1

Achieve Life Sciences, Inc News and around…

Latest news about Achieve Life Sciences, Inc (ACHV) common stock and company :

Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation
23 Nov, 2021 Yahoo! Finance

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the Company will host a Key Opinion Leader (KOL) virtual panel event on smoking and e-cigarette cessation on Thursday, December 2nd, 2021, at 1:00 PM EST. The event will feature a panel discussion,

Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
22 Nov, 2021 Yahoo! Finance

Following the fifth and final DSMC review, committee has concluded no concerns with cytisinicline safety or Phase 3 trial conductSEATTLE, Wash and VANCOUVER, British Columbia, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the completion of the fifth and final Data Safety Monitoring Committe

We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully
11 Nov, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

ACHV: Early 2022 Start to ORCA-3 and ORCA-V1
11 Nov, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Third Quarter 2021 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter results in a press release and held a conference call after market close on November 9, 2021. The company concurrently filed its Form 10-Q with the SEC. Highlights for the third quarter ended September 30th and to-date include: ➢ NIH

Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development
09 Nov, 2021 Yahoo! Finance

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced third quarter 2021 financial results and provided an update on the cytisinicline clinical development program. Recent Highlights Provided an update on the ORCA-2 Phase 3 clinical trial, including

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
09 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For ...

Achieve Life Sciences Announces Participation in November Investor Conferences
04 Nov, 2021 Yahoo! Finance

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that its management team will hold one-on-one investor meetings at the Alliance Global Partners’ (A.G.P.) Biotech & Specialty Pharma Conference and the Torrey Hills Capital Emerging Growth Conferenc

Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation
02 Nov, 2021 FinancialContent

TheFDA has signed offAchieve Life Sciences Inc's(NASDAQ: ACHV) Investigational New Drug (IND) application to ...

Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessation
02 Nov, 2021 Yahoo! Finance

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the U.S. Food and Drug Administration (FDA) has completed its review and accepted an Investigational New Drug (IND) application to investigate cytisinicline as a cessation treatment for nico

Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021
26 Oct, 2021 Yahoo! Finance

Seattle, WA/ Vancouver, BC , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third-quarter 2021 financial results and provide an update on the cytisinicline development program on Tuesday, November 9, 2021, at 4:30 PM EST. To access the webcast, log on to the Investor

Peek Under The Hood: ITOT Has 13% Upside
29 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

Achieve Life Sciences to Participate in Upcoming Investor Conferences
15 Sep, 2021 FinancialContent
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
14 Sep, 2021 FinancialContent
Achieve Life Sciences to Participate in Two Upcoming Investor Conferences
09 Sep, 2021 FinancialContent
Look Under The Hood: VXF Has 15% Upside
24 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Extended Market ETF (VXF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $213.01 per unit.

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
19 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

ACHV: ORCA-2 Fully Enrolled
16 Aug, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Second Quarter 2021 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported second quarter results in a press release and held a conference call after market close on August 12, 2021. The company concurrently filed its Form 10-Q with the SEC. Highlights for the second quarter ended June 30 th and to-date include: ➢

Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
13 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
11 Aug, 2021 FinancialContent

Gainers Hims & Hers Health (NYSE:HIMS) shares moved upwards by 12.53% to $8.44 during Wednesday's after-market session. This ...

Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
11 Aug, 2021 FinancialContent
12 Health Care Stocks Moving In Wednesday's Intraday Session
11 Aug, 2021 FinancialContent

Gainers Dyadic International (NASDAQ:DYAI) stock increased by 28.96% to $4.63 during Wednesday's regular session. ...

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen
11 Aug, 2021 FinancialContent
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
03 Aug, 2021 FinancialContent
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
22 Jul, 2021 FinancialContent
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
22 Jul, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! It's time to start off another busy day of trading with a look at the biggest pre-market stock movers for Thursday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Achieve Life Sciences, Inc (ACHV) is a NASDAQ Common Stock listed in , ,

970x250